Overview of Stereotaxis Financial Results for Q3 2025
Today, Stereotaxis (NYSE: STXS), a leader in surgical robotics designed for minimally invasive endovascular interventions, shared its financial results for the third quarter completed on September 30, 2025. The results demonstrate significant advancements in the company's offerings and inspire confidence among investors and stakeholders in the company’s direction.
Growth Initiatives and Progress
David Fischel, Chairman and CEO of Stereotaxis, highlighted the importance of commercial progress alongside technological innovation. He expressed enthusiasm about the company's stride towards achieving significant milestones, which are pivotal for realizing the potential of their comprehensive innovation strategy.
During the quarter, the company secured orders for two Genesis robotic systems from European hospitals, marking the establishment of new robotic programs. The reported recurring revenue reflected the usual summer slowdown in procedure volumes. However, the momentum generated from products like Map-iT, along with early-stage revenues from MAGiC and MAGiC Sweep, contributed positively. Notably, MAGiC Sweep achieved over three hundred thousand dollars in revenue within its first two months post-FDA clearance, underscoring initial demand for these innovative solutions.
Regulatory and Development Milestones
The pace of regulatory and development activities has accelerated according to Stereotaxis’ announcements, including receiving FDA clearance for the GenesisX robotic system. The company also achieved European CE Mark approval and submitted applications for its Synchrony digital cath lab technology. Multiple regulatory reviews for new electrophysiology and vascular catheters are ongoing, further enhancing Stereotaxis’ innovation pipeline.
Financial Highlights
The financial results for Q3 2025 revealed a total revenue of $7.5 million, which included $1.9 million in system revenue and $5.6 million from recurring sources. In comparison, this marks an increase from $4.4 million in system revenue and $4.8 million in recurring revenue from the same quarter last year. The system revenue figure reflects partial recognition for one capital system, while the growth in recurring revenue is bolstered by contributions from the entire quarter’s sales of Map-iT as well as initial revenues from Stereotaxis’ new robotically navigated devices.
For this quarter, the gross margin stood at 55%, with recurring revenue gross margins at 67%. Operating expenses totaled $10.7 million, of which $4.1 million represented non-cash charges. Adjusted operational expenses decreased to $6.6 million from the previous year’s $7.2 million, primarily due to lower general and administrative costs.
Cash Flow and Liquidity Status
By the end of September 2025, cash and cash equivalents amounted to $10.5 million, with no outstanding debt. A forthcoming capital influx of $4 million from a registered direct financing round would elevate this cash amount, ensuring Stereotaxis is well-positioned for future investments and product commercialization.
Looking Ahead: Fourth Quarter Expectations
As the company approaches the fourth quarter, it anticipates achieving revenues exceeding $9 million, encompassing anticipated system revenues of around $3 million and recurring revenues surpassing $6 million. These projections align with the company’s prior guidance of expecting over 20% annual revenue growth for the current year, indicating continued growth in both system and recurring revenue expected for 2026.
Stereotaxis’ strategic focus on advancing its product ecosystem aims to enhance market penetration and commercial capability while working towards achieving profitable operations.
Join the Conversation: Investor Call
Stereotaxis will be hosting a conference call and webcast for investors to discuss these results in detail. The call is accessible by dialing 800-715-9871 for those in the United States and Canada, and 646-307-1963 for international participants. Interested parties can also access the live webcast through the investor relations section on the Stereotaxis website.
About Stereotaxis
As a pioneer in surgical robotics, Stereotaxis specializes in minimally invasive solutions for complex endovascular procedures. Their commitment to innovation supports medical professionals in delivering high-quality patient care through enhanced precision and safety. Their technologies have positively impacted over 150,000 patients globally. For more updates and information about Stereotaxis’ advancements, please visit their official website.
Frequently Asked Questions
What were the total revenues reported by Stereotaxis for Q3 2025?
Stereotaxis reported total revenues of $7.5 million for the third quarter of 2025.
What is significant about the MAGiC Sweep?
The MAGiC Sweep generated substantial interest post-FDA clearance, resulting in over $300,000 in revenue within two months of its launch.
How has Stereotaxis’ operating expenses changed compared to last year?
The adjusted operating expenses decreased to $6.6 million in Q3 2025, down from $7.2 million in the same quarter last year.
What expectations does Stereotaxis have for Q4 2025?
For the fourth quarter, Stereotaxis expects revenue to exceed $9 million, with significant contributions anticipated from both system and recurring revenue streams.
How does the company plan to support its growth?
Stereotaxis aims to advance its product ecosystem, enhance commercialization efforts, and achieve profitability through efficient capital management and innovative technology advancements.
